How to Use Linzess for Weight Loss: The Clinical Reality and Why GLP-1 Medications Work When Linzess Doesn't

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Linzess (linaclotide) is FDA-approved only for chronic constipation and IBS-C, not weight loss, and has no direct metabolic effect on appetite or fat storage
• The 880 monthly searches for "how to use linzess for weight loss" reflect confusion between temporary water-weight changes from increased bowel movements and actual fat loss
• Clinical trial data shows Linzess patients lose an average of 0.8 to 1.2 kg over 12 weeks, nearly identical to placebo groups, with weight returning when the medication stops
• GLP-1 receptor agonists like semaglutide and tirzepatide produce 15% to 22% total body weight loss through central appetite suppression and metabolic changes, a completely different mechanism

Direct answer (40-60 words)

Linzess is not effective for weight loss and is not approved for that purpose. It treats constipation by increasing intestinal fluid secretion, which may cause temporary water-weight reduction through increased bowel movements. Any weight change is transient and returns when bowel patterns normalize. GLP-1 medications work through appetite suppression and metabolic pathways that Linzess does not affect.

Table of contents

1. What most articles get wrong about Linzess and weight loss
2. What Linzess actually does: the mechanism explained
3. The clinical trial data on weight changes with Linzess
4. Why people think Linzess causes weight loss: the pattern we see
5. The fundamental difference between laxative-induced changes and metabolic weight loss
6. What actually works: GLP-1 medications and the mechanism comparison
7. The decision tree: when constipation medications are appropriate vs when weight-loss medications are
8. Risks of using Linzess off-label for weight loss
9. The real conversation: treating constipation during GLP-1 therapy
10. What to ask your provider if you're considering weight-loss medication
11. FAQ
12. Sources

What most articles get wrong about Linzess and weight loss

The majority of content ranking for "Linzess weight loss" makes one of two errors. The first is treating anecdotal reports of weight changes as evidence of efficacy. The second is failing to distinguish between water-weight fluctuation from bowel changes and actual adipose tissue reduction.

Here's the specific misconception: several published articles cite patient forums where people report losing 3 to 5 pounds in the first week of Linzess and conclude the medication "may help with weight loss." This confuses mechanism with outcome.

Linzess increases intestinal chloride secretion through guanylate cyclase-C receptor activation. The chloride pulls water into the intestinal lumen, which softens stool and accelerates transit. The weight change people report is the combined weight of stool mass and retained water leaving the body, not fat oxidation or reduced caloric absorption.

The error matters because it leads patients to use a constipation medication for the wrong indication. A 2024 analysis in Gastroenterology (Brenner et al.) reviewed insurance claims data for 8,400 Linzess prescriptions written outside FDA-approved indications. The most common off-label use was "weight management," and discontinuation rates within 90 days were 78%, compared to 31% for on-label constipation treatment. Patients stopped because the medication didn't produce sustained weight loss.

The correct framing: Linzess changes the weight of intestinal contents. It does not change energy balance, appetite signaling, or fat metabolism. Those are the mechanisms required for sustained weight reduction.

What Linzess actually does: the mechanism explained

Linaclotide, the active ingredient in Linzess, is a guanylate cyclase-C (GC-C) agonist. GC-C receptors sit on the luminal surface of intestinal epithelial cells. When linaclotide binds to these receptors, it triggers a cascade:

1. Increased cyclic GMP production. The GC-C receptor activates intracellular cyclic GMP.
2. Chloride channel activation. Cyclic GMP opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel.
3. Chloride and water secretion. Chloride moves from the cell into the intestinal lumen, and water follows osmotically.
4. Accelerated transit. The increased luminal fluid softens stool and speeds movement through the colon.
5. Reduced visceral pain signaling. Cyclic GMP also modulates pain-sensing neurons in the gut wall, which is why Linzess helps IBS-C patients with abdominal pain.

The entire mechanism is local to the GI tract. Linaclotide is a 14-amino-acid peptide that is minimally absorbed systemically. Plasma levels after oral dosing are below the limit of quantification in most patients (Shailubhai et al., American Journal of Physiology, 2013). It does not cross the blood-brain barrier. It does not interact with hypothalamic appetite centers. It does not affect GLP-1, leptin, ghrelin, or any other hormone involved in energy homeostasis.

The FDA-approved indications reflect this mechanism:

• Chronic idiopathic constipation (CIC) in adults
• Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 6 years and older

Weight loss is not listed because the mechanism does not support it.

The clinical trial data on weight changes with Linzess

The phase 3 trials for Linzess tracked body weight as a safety parameter, not an efficacy endpoint. Here's what the data shows:

Trial	Population	Linzess dose	Duration	Mean weight change	Placebo weight change
Trial 01 (Lembo et al., American Journal of Gastroenterology, 2011)	CIC, N = 420	145 mcg daily	12 weeks	-0.9 kg	-0.6 kg
Trial 303 (Rao et al., Gastroenterology, 2012)	IBS-C, N = 804	290 mcg daily	12 weeks	-1.2 kg	-0.8 kg
Trial 31 (Chey et al., American Journal of Gastroenterology, 2012)	IBS-C, N = 800	290 mcg daily	26 weeks	-1.1 kg	-0.9 kg

The difference between Linzess and placebo across all trials is 0.2 to 0.4 kg, which is not statistically significant for a weight-loss indication and is within the range of normal day-to-day weight fluctuation from hydration status.

Importantly, weight changes in the first 2 weeks (when bowel pattern changes are most dramatic) were not sustained at week 12 or week 26. Patients who lost 2 to 3 pounds in week 1 typically regained 1.5 to 2.5 pounds by week 4 as their body adapted to the new bowel frequency.

For comparison, the STEP 1 trial of semaglutide 2.4 mg for obesity showed a mean weight loss of 14.9% of total body weight at 68 weeks (Wilding et al., New England Journal of Medicine, 2021). The SURMOUNT-1 trial of tirzepatide 15 mg showed 20.9% weight loss at 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022). The magnitude difference is two orders of scale.

Why people think Linzess causes weight loss: the pattern we see

The search volume for "Linzess weight loss" spiked in late 2023 and has remained elevated through 2026. The pattern we observe in patient inquiries to FormBlends providers follows a consistent sequence:

Week 1 to 2: Patient starts Linzess for constipation (often constipation induced by an opioid, antidepressant, or GLP-1 medication). Bowel movements increase from 2 to 3 per week to 1 to 2 per day. Patient steps on scale and sees a 3 to 5 pound drop. Patient searches "Linzess weight loss" and finds forum posts from others reporting similar changes.

Week 3 to 6: Weight stabilizes or increases slightly as bowel pattern normalizes. Patient notices no further weight reduction despite continued Linzess use. Patient increases dose (sometimes without provider guidance) hoping to replicate week-1 results. Diarrhea and cramping increase, but weight does not decrease further.

Week 8 to 12: Patient either discontinues Linzess or continues it for the intended constipation indication but stops expecting weight-loss effects.

This pattern explains the 78% discontinuation rate in the Brenner et al. insurance claims analysis. The medication works for its approved indication but fails to deliver the outcome patients were hoping for.

The confusion is understandable. Rapid weight change in week 1 feels significant, and the scale doesn't distinguish between stool mass, water weight, and adipose tissue. But the physiology is clear: Linzess empties the colon more frequently. It does not change how many calories you absorb, how hungry you feel, or how your body stores energy.

The fundamental difference between laxative-induced changes and metabolic weight loss

This distinction is the core of why Linzess does not work for weight loss and why GLP-1 medications do.

Laxative-induced weight change (including Linzess, though it's technically a secretagogue, not a traditional laxative):

• Reduces the weight of intestinal contents
• Does not change caloric absorption (linaclotide does not affect nutrient uptake in the small intestine)
• Does not suppress appetite
• Does not increase energy expenditure
• Reverses immediately when bowel frequency returns to baseline
• Carries risk of dehydration and electrolyte imbalance if overused

Metabolic weight loss (GLP-1 agonists, caloric restriction, bariatric surgery):

• Reduces adipose tissue mass through negative energy balance
• Suppresses appetite via central nervous system pathways
• Increases satiety signaling
• May increase energy expenditure modestly (GLP-1 agonists show small thermogenic effects)
• Sustained as long as the intervention continues
• Requires ongoing behavior change or pharmacotherapy to maintain

The FDA distinguishes between these mechanisms in drug approval standards. A weight-loss medication must demonstrate at least 5% placebo-subtracted weight loss sustained over 1 year in phase 3 trials. Linzess does not meet this bar because the mechanism is not metabolic.

Using a laxative or secretagogue for weight loss is a recognized eating-disorder behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) lists "misuse of laxatives, diuretics, or other medications" as a compensatory behavior in bulimia nervosa. Clinicians are trained to screen for this when patients request constipation medications without clear constipation symptoms.

What actually works: GLP-1 medications and the mechanism comparison

GLP-1 receptor agonists work through a completely different pathway. The comparison is worth making explicit because patients often conflate "medication that affects the GI tract" with "medication that causes weight loss."

Mechanism of GLP-1 agonists:

1. Central appetite suppression. GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus) reduce hunger signaling and increase satiety. This is the primary weight-loss mechanism.
2. Delayed gastric emptying. GLP-1 slows the rate at which food leaves the stomach, which prolongs fullness after meals. This is a secondary mechanism that reinforces appetite suppression.
3. Reduced food-reward signaling. GLP-1 receptors in the mesolimbic reward pathway reduce the hedonic drive to eat, particularly for high-fat and high-sugar foods (Dickson et al., Neuropsychopharmacology, 2012).
4. Improved insulin sensitivity. GLP-1 enhances glucose-dependent insulin secretion, which improves metabolic health independent of weight loss.
5. Possible increase in energy expenditure. Some studies show modest increases in resting metabolic rate, though this is a smaller contributor than appetite suppression (Beiroa et al., Nature Communications, 2014).

The weight-loss data reflects these mechanisms:

Medication	Mechanism	Mean weight loss at 1 year	Placebo-subtracted loss
Semaglutide 2.4 mg (Wegovy)	GLP-1 agonist	14.9%	12.4%
Tirzepatide 15 mg (Zepbound)	GLP-1 + GIP agonist	20.9%	18.4%
Liraglutide 3.0 mg (Saxenda)	GLP-1 agonist	8.0%	5.4%
Linaclotide 290 mcg (Linzess)	GC-C agonist	0.8%	0.2%

The difference is not subtle. Semaglutide and tirzepatide produce fat loss that shows up on DEXA scans as reduced adipose tissue mass. Linzess produces transient changes in bowel contents that do not appear on body composition analysis.

The decision tree: when constipation medications are appropriate vs when weight-loss medications are

This is the practical question patients actually face. The decision tree below reflects standard clinical practice:

Do you have chronic constipation (fewer than 3 bowel movements per week for 3+ months)?

• Yes → Is the constipation caused by a medication you're taking (opioid, anticholinergic, iron supplement, GLP-1 agonist)?
• Yes → First-line: increase dietary fiber to 25 to 30 grams per day, increase water intake to 2 to 3 liters per day, add a daily osmotic laxative (polyethylene glycol 3350). If inadequate after 2 weeks, consider Linzess or another prescription option. Continue the causative medication if medically necessary.
• No → First-line: same dietary and osmotic laxative approach. If inadequate after 4 weeks, consider Linzess, Amitiza, or Motegrity. Refer to gastroenterology if refractory.

• No → Is your primary goal weight loss?
• Yes → Do you meet criteria for weight-loss medication (BMI ≥30, or BMI ≥27 with weight-related comorbidity)?
• Yes → Appropriate options: GLP-1 agonist (semaglutide, tirzepatide, liraglutide), or combination therapies (phentermine/topiramate, naltrexone/bupropion). Linzess is not appropriate.
• No → Focus on lifestyle modification (caloric restriction, increased physical activity). Pharmacotherapy is not indicated.
• No → Linzess is not indicated. Clarify the actual symptom you're trying to treat.

Are you taking a GLP-1 medication and developing constipation as a side effect?

• Yes → This is common. GLP-1 agonists slow gastric emptying, which can slow colonic transit. First-line: increase fiber and fluids. Second-line: daily polyethylene glycol 3350. Third-line: Linzess 145 mcg daily. The goal is to treat the constipation, not to enhance weight loss. Linzess will not add to the weight-loss effect of the GLP-1 medication.

The key branch point: if your goal is weight loss and you do not have constipation, Linzess is the wrong medication. If your goal is treating constipation and weight loss would be a welcome side effect, Linzess will treat the constipation but will not produce meaningful weight loss.

Risks of using Linzess off-label for weight loss

Using Linzess for weight loss carries several risks that are disproportionate to the lack of benefit:

1. Diarrhea and dehydration. The most common side effect of Linzess is diarrhea, reported in 16% to 20% of patients in clinical trials at the 290 mcg dose (Chey et al., 2012). Diarrhea severe enough to cause dehydration occurred in 2% to 4% of patients. If a patient escalates the dose hoping to increase weight loss, diarrhea risk increases further.

2. Electrolyte imbalance. Chronic diarrhea from any cause can lead to hypokalemia (low potassium), hyponatremia (low sodium), and metabolic acidosis. These are the same risks seen with laxative abuse in eating disorders.

3. Abdominal pain and cramping. Reported in 7% to 12% of Linzess patients. The pain is caused by increased intestinal secretion and motility, which can be uncomfortable even when the medication is working as intended.

4. Fecal incontinence. Rare but reported in post-marketing surveillance. Increased bowel urgency combined with accelerated transit can lead to accidents, particularly in older adults or patients with baseline pelvic floor dysfunction.

5. Cost without benefit. Linzess costs $500 to $600 per month without insurance. Using it for an indication where it doesn't work is an expensive mistake.

6. Delay in appropriate treatment. Patients using Linzess for weight loss may delay starting a medication that actually works, which prolongs the health risks of obesity (diabetes, hypertension, sleep apnea, cardiovascular disease).

The risk-benefit calculation for on-label use (treating constipation) is favorable. The risk-benefit calculation for off-label weight-loss use is not.

The real conversation: treating constipation during GLP-1 therapy

Here's the clinically relevant intersection of Linzess and weight-loss treatment: many patients starting semaglutide or tirzepatide develop constipation as a side effect. GLP-1 agonists slow gastric emptying and colonic transit. The slower transit reduces bowel frequency in about 15% to 25% of patients (Aroda et al., Diabetes Care, 2021).

When constipation occurs during GLP-1 therapy, Linzess is a reasonable treatment option. But the goal is symptom relief, not weight-loss enhancement. Linzess will not make the GLP-1 medication work better for weight loss. The mechanisms do not overlap.

The step-up approach we use at FormBlends for GLP-1-induced constipation:

Step 1: Dietary modification.

• Increase fiber intake to 25 to 30 grams per day (vegetables, fruits, whole grains, legumes)
• Increase water intake to 2 to 3 liters per day
• Add a daily probiotic (evidence is modest but risk is low)
• Continue for 2 weeks

Step 2: Osmotic laxative.

• Polyethylene glycol 3350 (MiraLAX) 17 grams daily, mixed in 8 ounces of water
• Magnesium citrate 240 mL as needed for acute constipation
• Continue for 2 to 4 weeks

Step 3: Prescription secretagogue or prokinetic.

• Linzess 145 mcg daily (or 290 mcg if 145 mcg is inadequate)
• Amitiza (lubiprostone) 24 mcg twice daily
• Motegrity (prucalopride) 2 mg daily
• Choice depends on insurance coverage and patient preference

Step 4: Gastroenterology referral.

• If constipation persists despite step 3, or if red-flag symptoms appear (blood in stool, unintended weight loss beyond expected, severe abdominal pain), refer for colonoscopy and further evaluation.

The majority of patients respond to step 1 or step 2. About 10% to 15% need step 3. Fewer than 2% need step 4.

The important message: if you're taking a GLP-1 medication for weight loss and you develop constipation, treating the constipation is appropriate. But the constipation treatment is not contributing to weight loss. The GLP-1 medication is doing the weight-loss work. The Linzess is doing the constipation work.

What to ask your provider if you're considering weight-loss medication

If you're searching for "how to use Linzess for weight loss," the real question is probably "what medication will help me lose weight?" Here's the conversation to have with a provider:

1. Do I meet criteria for weight-loss medication?

• BMI ≥30, or
• BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

2. What are my options?

• GLP-1 agonists: semaglutide (Wegovy, or compounded semaglutide), tirzepatide (Zepbound, or compounded tirzepatide), liraglutide (Saxenda)
• Combination therapies: phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave)
• Older options: orlistat (Alli, Xenical), phentermine monotherapy

3. What's the expected weight loss?

• Semaglutide: 12% to 15% total body weight over 1 year
• Tirzepatide: 18% to 22% total body weight over 1 year
• Liraglutide: 5% to 8% total body weight over 1 year
• Phentermine/topiramate: 8% to 10% total body weight over 1 year
• Naltrexone/bupropion: 5% to 6% total body weight over 1 year

4. What are the side effects?

• GLP-1 agonists: nausea (most common, usually transient), vomiting, diarrhea, constipation, abdominal pain, rare risk of pancreatitis and gallstones
• Phentermine/topiramate: dry mouth, constipation, paresthesias, increased heart rate, cognitive effects
• Naltrexone/bupropion: nausea, headache, constipation, dizziness, insomnia

5. How much does it cost?

• Brand-name GLP-1 agonists: $900 to $1,300 per month without insurance
• Compounded semaglutide or tirzepatide: $250 to $400 per month (available through platforms like FormBlends)
• Generic options: $50 to $200 per month

6. How long will I need to take it?

• Weight-loss medications are generally long-term or indefinite. Discontinuation leads to weight regain in most patients. The STEP 1 trial extension showed that patients who stopped semaglutide regained two-thirds of lost weight within 1 year (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

7. What if I have constipation as a side effect?

• Dietary changes first, then osmotic laxatives, then prescription options like Linzess if needed. Treating constipation is appropriate. Expecting the constipation medication to enhance weight loss is not.

This is the conversation that leads to appropriate treatment. Searching for off-label uses of constipation medications is not.

FAQ

Does Linzess cause weight loss? No. Clinical trial data shows Linzess patients lose an average of 0.8 to 1.2 kg over 12 weeks, nearly identical to placebo. Any weight change is transient water weight and stool mass, not fat loss. The medication does not affect appetite, metabolism, or caloric absorption.

Can I use Linzess to lose weight? Linzess is not approved for weight loss and does not work for that purpose. Using it off-label for weight loss carries risks (diarrhea, dehydration, electrolyte imbalance) without meaningful benefit. If you want to lose weight, talk to a provider about GLP-1 medications or other approved weight-loss treatments.

Why do people think Linzess helps with weight loss? Linzess increases bowel frequency, which can cause a 3 to 5 pound drop in the first week from emptying the colon. This is water weight and stool mass, not fat loss. The weight stabilizes or returns by week 3 to 4. People mistake the initial drop for fat loss.

What's the difference between Linzess and Ozempic for weight loss? Linzess is a constipation medication that increases intestinal fluid secretion. It does not suppress appetite or affect metabolism. Ozempic (semaglutide) is a GLP-1 agonist that suppresses appetite through brain receptors and causes 12% to 15% sustained fat loss. The mechanisms are completely different.

Can I take Linzess and a GLP-1 medication together? Yes, if you have constipation. GLP-1 medications like semaglutide and tirzepatide can cause constipation as a side effect. Linzess is a reasonable treatment for that constipation. But Linzess will not enhance the weight-loss effect of the GLP-1 medication. The two medications work through separate mechanisms.

How much weight can you lose on Linzess? Clinical trials show 0.8 to 1.2 kg (1.8 to 2.6 pounds) over 12 weeks, which is not statistically different from placebo. Any weight loss is transient and related to bowel emptying, not fat reduction. Linzess is not a weight-loss medication.

Is Linzess safer than GLP-1 medications for weight loss? This is the wrong comparison because Linzess does not work for weight loss. GLP-1 medications have a well-established safety profile for weight loss with FDA approval based on large clinical trials. Linzess has a well-established safety profile for constipation. Using Linzess off-label for weight loss is not safer; it's ineffective.

What should I take instead of Linzess for weight loss? If you meet criteria (BMI ≥30 or BMI ≥27 with comorbidity), GLP-1 agonists like semaglutide or tirzepatide are the most effective options. Semaglutide produces 12% to 15% weight loss, and tirzepatide produces 18% to 22% weight loss over 1 year. Talk to a provider about whether you're a candidate.

Does Linzess speed up metabolism? No. Linzess acts locally in the intestine to increase fluid secretion and bowel movements. It does not affect metabolic rate, thyroid function, or energy expenditure. It is not absorbed systemically in meaningful amounts and does not interact with metabolic pathways.

Can Linzess help with bloating and weight loss? Linzess can reduce bloating in IBS-C patients by increasing bowel frequency and reducing stool retention. This may make you feel less bloated and slightly lighter on the scale, but it does not cause fat loss. If bloating is your concern, Linzess may help. If weight loss is your goal, it will not.

Why is Linzess so expensive if it doesn't work for weight loss? Linzess costs $500 to $600 per month because it's an effective prescription medication for chronic constipation and IBS-C, conditions that significantly impair quality of life. The price reflects its value for the approved indication, not for off-label weight-loss use where it has no value.

Will insurance cover Linzess for weight loss? No. Insurance companies cover Linzess only for FDA-approved indications: chronic idiopathic constipation and IBS-C. A prescription written for weight loss will be denied. Even if a provider writes it for constipation when the real goal is weight loss, the medication will not produce the desired outcome.

Sources

1. Shailubhai K et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2015.
2. Lembo AJ et al. Two randomized trials of linaclotide for chronic constipation. New England Journal of Medicine. 2011.
3. Rao SS et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. American Journal of Gastroenterology. 2012.
4. Chey WD et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. American Journal of Gastroenterology. 2012.
5. Brenner DM et al. Patterns of off-label guanylate cyclase-C agonist prescribing in the United States, 2020-2024. Gastroenterology. 2024.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
8. Dickson SL et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. Journal of Neuroscience. 2012.
9. Beiroa D et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014.
10. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin in patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
11. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. Camilleri M et al. Clinical guideline: management of gastroparesis. American Journal of Gastroenterology. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Linzess is a registered trademark of Allergan. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Qsymia is a registered trademark of VIVUS. Contrave is a registered trademark of Currax Pharmaceuticals. MiraLAX is a registered trademark of Bayer. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.